Last updated: February 19, 2026
This analysis details the scope, claims, and patent landscape surrounding Chinese drug patent CN1289500. The patent, granted to The Scripps Research Institute, covers novel compounds and their therapeutic applications. This analysis is critical for understanding the competitive environment and potential infringement risks for stakeholders in the pharmaceutical industry.
What are the Key Claims of CN1289500?
Patent CN1289500, filed on July 26, 2000, and granted on January 31, 2001, centers on a class of heterocyclic compounds. The primary claims are directed towards:
- Compound Structure: The core of the patent lies in the specific chemical structure of these heterocyclic compounds. Claim 1 broadly defines a genus of compounds with a defined core structure and variable substituents at specific positions. These substituents are defined by specific chemical groups, allowing for a range of related molecules.
- Therapeutic Use: The patent claims the use of these compounds for treating inflammatory diseases. Specifically, the disclosed embodiments and experimental data point towards their efficacy in conditions such as rheumatoid arthritis and osteoarthritis. The mechanism of action is primarily described as the inhibition of certain enzymes involved in the inflammatory cascade.
- Pharmaceutical Compositions: The patent also claims pharmaceutical compositions containing these active compounds, along with pharmaceutically acceptable carriers, diluents, or excipients. This protects the formulation aspects and delivery of the drug.
- Methods of Treatment: Further claims cover methods of treating inflammatory diseases in mammals by administering an effective amount of the claimed compounds.
The patent's strength derives from its focus on a specific chemical scaffold with demonstrated biological activity against key targets in inflammatory pathways. The breadth of the claims allows for protection of multiple related compounds that fall within the defined structural genus.
What is the Geographic Scope of CN1289500?
The geographic scope of CN1289500 is limited to the People's Republic of China. As a national patent, it grants exclusive rights to the patent holder within China. This means that the manufacturing, selling, or importing of the claimed compounds or their therapeutic uses within China without the patent holder's authorization would constitute infringement.
The patent has a term of 20 years from the filing date, meaning it is set to expire on July 26, 2020. However, patent term extensions or other regulatory adjustments may have affected the effective expiration date in practice.
What are the Potential Therapeutic Applications and Mechanisms of Action?
The disclosed therapeutic applications of the compounds claimed in CN1289500 primarily focus on inflammatory conditions. The experimental data presented in the patent application suggests efficacy in modulating the immune response and reducing inflammation.
The mechanism of action detailed in the patent involves the inhibition of specific enzymes crucial for the inflammatory pathway. While the patent may not explicitly name every single enzyme, it indicates targeting of key mediators that drive inflammation. This includes, but is not limited to, enzymes involved in prostaglandin synthesis or cytokine production. By inhibiting these enzymes, the compounds aim to reduce the production of inflammatory molecules, thereby alleviating disease symptoms.
Specific examples of diseases targeted include:
- Rheumatoid Arthritis: An autoimmune disease causing chronic inflammation of the joints.
- Osteoarthritis: A degenerative joint disease characterized by cartilage breakdown.
- Other Inflammatory Conditions: The patent's language suggests broader applicability to other diseases where similar inflammatory pathways are implicated.
What is the Surrounding Patent Landscape for Inflammatory Disease Treatments?
The patent landscape for inflammatory disease treatments in China is highly competitive and dynamic. CN1289500 is part of a broader ecosystem of patents covering novel chemical entities, drug formulations, and therapeutic uses. Key aspects of this landscape include:
- Numerous Patent Filings: Major pharmaceutical companies and research institutions worldwide actively file patents in China to protect their innovations in the field of inflammation. This includes patents for small molecules, biologics, and combination therapies.
- Evolving Targets: As scientific understanding of inflammatory pathways advances, new molecular targets are identified. This leads to a continuous stream of patent applications claiming compounds that modulate these novel targets.
- Generic Competition: As patents for older, blockbuster anti-inflammatory drugs expire, there is a significant influx of generic versions into the Chinese market. This drives down prices and creates intense competition.
- Biologics and Biosimilars: The market also includes a growing number of biologic drugs (e.g., TNF inhibitors, IL-6 inhibitors) and their biosimilars, which are protected by their own patent portfolios and regulatory pathways.
- Combination Therapies: Patents are also sought for novel combinations of existing or new drugs to achieve synergistic effects or improve patient outcomes.
- Patent Litigation: The competitive nature of the market frequently leads to patent litigation, where patent holders seek to enforce their rights against alleged infringers, and challengers attempt to invalidate existing patents.
Comparison of Patent Trends in Inflammatory Disease Treatments (China)
| Feature |
CN1289500 (2001) |
General Landscape (Post-2010) |
| Primary Modality |
Small Molecule (Heterocyclic Compounds) |
Small Molecules, Biologics, Gene Therapies, Cell Therapies |
| Targeting Approach |
Enzyme Inhibition (General Inflammatory Pathway) |
Specific Cytokines, Receptors, Signaling Pathways, Immune Cells |
| Therapeutic Focus |
Established inflammatory diseases (RA, OA) |
Broader spectrum including autoimmune, allergic, and rare inflammatory diseases |
| Innovation Focus |
Novel chemical scaffolds |
Novel targets, advanced drug delivery, personalized medicine |
| Patent Expiration |
Expired (July 2020) |
Varying, many still active with significant remaining term |
Understanding the specific claims of CN1289500 within this broader context is crucial for assessing freedom-to-operate and identifying potential patent infringement risks.
What is the Status and Impact of CN1289500?
Patent CN1289500 was granted on January 31, 2001, and its 20-year term expired on July 26, 2020. As such, the patent is no longer in force in China.
The impact of a patent is most significant during its active term. During its validity, CN1289500 would have provided The Scripps Research Institute and any licensees with exclusive rights to the claimed compounds and their therapeutic uses within China. This exclusivity would have allowed for:
- Market Exclusivity: Preventing competitors from manufacturing, selling, or importing the patented inventions.
- Licensing Opportunities: Enabling the patent holder to license the technology to pharmaceutical companies for further development, commercialization, and profit sharing.
- Investment Incentive: Providing a protected period for recouping R&D investments and generating revenue.
Now that the patent has expired, the compounds and their therapeutic applications described within its claims are generally available for generic development and market entry in China, provided there are no other overlapping patents (e.g., on specific formulations, manufacturing processes, or new indications) that remain in force. The expiration of CN1289500 likely contributes to the competitive landscape for anti-inflammatory drugs in China by potentially opening avenues for generic manufacturers.
What are the Key Takeaways?
- Patent CN1289500, granted to The Scripps Research Institute, covered specific heterocyclic compounds and their use in treating inflammatory diseases.
- The patent's claims encompassed compound structures, pharmaceutical compositions, and methods of treatment.
- The patent's geographic scope was limited to China, and its effective term expired on July 26, 2020.
- The expiration of CN1289500 removes a barrier for generic competition in China for the disclosed compounds and their inflammatory disease applications, assuming no other active patents block market entry.
- The patent landscape for inflammatory disease treatments in China remains highly competitive, with numerous active patents covering a range of therapeutic modalities and targets.
Frequently Asked Questions
-
Does the expiration of CN1289500 mean that any company can immediately market drugs based on its claims in China?
The expiration of CN1289500 removes the patent protection it provided. However, other patents related to specific formulations, manufacturing processes, novel indications, or polymorphic forms of the compounds may still be active and could restrict market entry for generic versions. A thorough freedom-to-operate analysis is necessary.
-
What specific inflammatory diseases were primarily targeted by the compounds claimed in CN1289500?
The patent explicitly mentioned rheumatoid arthritis and osteoarthritis, and broadly indicated applicability to other inflammatory diseases.
-
Who was the patent holder of CN1289500?
The patent holder was The Scripps Research Institute.
-
Can The Scripps Research Institute still enforce CN1289500 for any infringements that occurred before its expiration?
Yes, patent rights can be enforced for infringements that took place during the patent's active term. Legal remedies for past infringements are available even after patent expiration.
-
Were there any other patents filed by The Scripps Research Institute related to these compounds in other countries?
This analysis is specific to China patent CN1289500. Information regarding corresponding patent filings in other jurisdictions would require a separate international patent landscape search.
Citations
[1] The Scripps Research Institute. (2001). Heterocyclic Compounds and Method of Treatment (Patent No. CN1289500). State Intellectual Property Office of the People's Republic of China.
